Age, median (IQR)-yr | 47 (40–55) |
Age group, n (%) | |
<50 years | 394 (59) |
≥50 years | 273 (41) |
Sex, n (%) | |
Male | 635 (95) |
Female | 32 (5) |
CD4 cell counts, median (IQR)-cells/µL | 587 (444–757) |
HIV-RNA, n (%) | |
≤ 20 copies/mL | 548 (82) |
20‒49 copies/mL | 52 (15) |
≥ 50 copies/mL | 20 (3) |
ART regimen consisting of the following tablet sizes, n (%) | |
Tablets size less than 15 mm | 342 (51) |
Tablets size over 15 mm | 325 (49) |
Duration of receipt of overall ART (medication history), n (%) | |
≤ 3 years | 95 (14) |
≥ 3 years | 572 (86) |
Employment, n (%) | |
Employed | 530 (79) |
Unemployed | 110 (16) |
Unknown | 27 (4) |
Frequency of daily dosage, n (%) | |
Once a day | 392 (59) |
Twice a day | 128 (19) |
Three times a day | 82 (12) |
4 or more times a day | 65 (10) |
Concomitant medications, n (%) | |
With concomitant medications | 379 (57) |
Without concomitant medications | 285 (43) |
Unknown | 3 |
Daily tablet dosage (including concomitant medications), n (%) | |
1 tablet/day | 193 (29) |
2 tablets/day | 139 (21) |
3 tablets/day | 99 (15) |
4 or more tablets/day | 236 (35) |